Zenith Drugs
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · TTM
- ROCE
- 9.08%
- Debt to Equity
- 0.75
- EPS (TTM)
- —
- Book Value
- ₹42.76
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 0.92
- ROE
- 5.76%
- Dividend Yield
- 1.35%
- EBITDA
- ₹19.00 Cr
- 52W High
- ₹63.60
- 52W Low
- ₹33.30
- Day Range
- ₹36.80 – ₹39.55
- Volume
- 17,600
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Zenith Drugs (this company) | ₹39.55 | — | ₹63 Cr | 0.92 | 1.35% | 5.76% | 9.08% | — | — |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.70% | 16.25% | 16.65% | ₹28,324 Cr | ₹3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 84/100
Category scores
- Quality
- 76
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 62
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 77
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 17
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 43
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.94 times its book value
Weaknesses
5- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 12.5% over last 3 years.
- Earnings include an other income of Rs.4.89 Cr.
- Company has high debtors of 157 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 6 | 5 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Bearish
Overall
Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 49.25
- Neutral
- MACD (12,26,9)
- −1.33
- Bullish
- SMA (50)
- 41.72
- Bearish
- SMA (200)
- 44.25
- Bearish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +18.89% |
|---|---|
| 3Y | +14.14% |
| 1Y | +29.55% |
Net profit
| 5Y | +5.92% |
|---|---|
| 3Y | −7.17% |
| 1Y | −42.86% |
Operating cash flow
| 5Y | Turned positive |
|---|---|
| 3Y | Turned positive |
| 1Y | Turned positive |
Operating margin· change in pp
| 5Y | −2.70 pp |
|---|---|
| 3Y | −0.81 pp |
| 1Y | −3.59 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2020 | ₹78.00 Cr |
|---|---|
| Mar 2021 | ₹72.00 Cr |
| Mar 2022 | ₹92.00 Cr |
| Mar 2023 | ₹115 Cr |
| Mar 2024 | ₹131 Cr |
| Mar 2025 | ₹132 Cr |
| Mar 2026 | ₹171 Cr |
Net profit by year
| Mar 2020 | ₹3.00 Cr |
|---|---|
| Mar 2021 | ₹3.00 Cr |
| Mar 2022 | ₹3.00 Cr |
| Mar 2023 | ₹5.00 Cr |
| Mar 2024 | ₹10.00 Cr |
| Mar 2025 | ₹7.00 Cr |
| Mar 2026 | ₹4.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 69 | 62 | 68 | 66 | 78 | 93 |
| Expenses | 58 | 56 | 61 | 59 | 72 | 87 |
| Operating Profit | 11 | 6 | 7 | 7 | 6 | 6 |
| OPM % | 16% | 9% | 10% | 10% | 8% | 6% |
| Other Income | −1 | 2 | 1 | 1 | 2 | 3 |
| Interest | 1 | 2 | 1 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 2 | 3 | 3 |
| PBT | 8 | 6 | 6 | 4 | 2 | 3 |
| Tax % | 25% | 32% | 0% | 59% | 0% | 48% |
| Net Profit | 6 | 4 | 6 | 1 | 2 | 2 |
| EPS (₹) | 4.75 | 2.24 | 3.34 | 0.84 | 1.36 | 0.94 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 78 | 72 | 92 | 115 | 131 | 132 | 171 |
| Expenses | 71 | 64 | 85 | 105 | 114 | 119 | 158 |
| Operating Profit | 7 | 7 | 7 | 9 | 17 | 14 | 12 |
| OPM % | 9% | 10% | 8% | 8% | 13% | 10% | 7% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 2 | 5 |
| Interest | 1 | 1 | 2 | 2 | 3 | 4 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 3 | 6 |
| PBT | 5 | 5 | 4 | 7 | 13 | 9 | 5 |
| Tax % | 30% | 33% | 27% | 27% | 28% | 23% | 27% |
| Net Profit | 3 | 3 | 3 | 5 | 10 | 7 | 4 |
| EPS (₹) | — | — | — | — | 5.56 | 4.18 | 2.3 |
| Div. Payout % | 0% | 0% | 0% | 0% | 9% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.4 | 0.4 | 0.4 | 0.4 | 17 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 52 | 56 |
| Borrowings | 12 | 15 | 17 | 25 | 24 | 49 | 55 |
| Other Liabilities | 25 | 21 | 37 | 54 | 48 | 44 | 59 |
| Total Liabilities | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
| Fixed Assets | 6 | 9 | 10 | 11 | 11 | 40 | 37 |
| CWIP | 3 | 0 | 0 | 0 | 4 | 3 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 35 | 37 | 56 | 86 | 119 | 118 | 136 |
| Total Assets | 44 | 47 | 66 | 97 | 134 | 161 | 188 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 3 | −1 | 5 | −4 | −16 | −5 | 9 |
| Investing | −5 | −2 | −3 | −2 | −5 | −31 | −14 |
| Financing | 1 | 3 | −1 | 6 | 30 | 28 | 5 |
| Net Cash Flow | 0 | 0 | 1 | 0 | 9 | −8 | 0 |
| Free Cash Flow | −1 | −2 | 2 | −6 | −21 | −37 | −5 |
| CFO/OP | 71 | 7 | 88 | −27 | −70 | −25 | 86 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | 157 | 188 | 167 | 157 |
| Inventory Days | 29 | 52 | 61 | — | 249 | 277 | 257 |
| Days Payable | 155 | 155 | 173 | — | 412 | 281 | 337 |
| Cash Conversion Cycle | −7 | 17 | 16 | 157 | 25 | 163 | 77 |
| Working Capital Days | 14 | 24 | 21 | 39 | 111 | 91 | 74 |
| ROCE % | — | 28% | 24% | 25% | 28% | 13% | 9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Zenith Drugs insights
63 extracted metrics across FY20–FY26.
Documents
- 8 Sep 2026
- 15 Jun 2026
- 8 Jun 2026
- 21 May 2026
- 17 Mar 2025
- 10 Oct 2026
- 30 Sep 2026
- 29 Sep 2026
- 29 Sep 2026
Frequently Asked Questions about Zenith Drugs
What does Zenith Drugs Ltd do?
Where is Zenith Drugs Ltd (ZENITHDRUG) listed?
Which sector does Zenith Drugs Ltd belong to?
What is the 52-week high and low of Zenith Drugs Ltd?
Does Zenith Drugs Ltd pay dividends?
What is the Return on Equity (ROE) of Zenith Drugs Ltd?
Company Information
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing and trading of medicines
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZENITHDRUG.md for Zenith Drugs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.